At LAVA, we are focused on developing our Gammabody platform to transform cancer therapy. Our Gammabody platform generates bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. This approach is designed to complement natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade.  Our Gammabody® platform drug candidates have, in preclinical studies, demonstrated superior efficacy and safety profiles compared to other bispecific T cell engagers approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer.